Meeting
2023 ASCO Annual Meeting
Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial.
Authors
Benedetta Pellegrino
University of Parma, Parma, Italy
Benedetta Pellegrino , Ettore Capoluongo , Nicoletta Campanini , Antonino Musolino , Angelica Sikokis , Chiara Casartelli , Nicola Normanno , Laura Arenare , Violeta Serra , Alba Llop-Guevara , Carmela Nardelli , Luca Beltrame , Daniela Califano , Maurizio D'Incalci , Cristin Roma , Delia Mezzanzanica , Gustavo Baldassarre , Francesco Perrone , Sergio Marchini , Sandro Pignata
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5527)
DOI
10.1200/JCO.2023.41.16_suppl.5527
Abstract #
5527
Poster Bd #
222
Abstract Disclosures
Similar Posters
First Author: Emmanouil S. Saloustros
Poster
2023 ASCO Annual Meeting
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
First Author: Helene Blons
Poster
2023 ASCO Annual Meeting
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
First Author: Lorena Incorvaia
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan